Clinical trials: Post Hematopoietic Stem Cell Transplant
Hematopoietic Stem Cell Transplant
Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem Cell Transplant
The primary objective of this study is to compare the 2-year progression free survival without acute graft versus host disease (GvHD) (aGvHD) grade III-IV or without moderate or severe chronic (cGVHD) after transplant from…
- Trial name
- ALTERGREF (NCT03250546)
- Testing
- transplant from a haplo-identical donor, transplant from a non related donor
- Where
- 2 sites in France
- Volunteers
- 184 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Graft-versus-Host Disease
A Study of iMSC for the Prevention of Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
An open-label, randomized, controlled clinical trial to explore the efficacy and safety of iMSC in preventing the development of acute graft-versus-host disease of degree III-IV in patients after allogeneic hematopoietic stem…
- Trial name
- NCT06949267
- Testing
- iMSC, conventional aGVHD prophylaxis
- Volunteers
- 56 people
- Sponsor
- Ruijin Hospital
Relapsed Adult ALL, B Cell Leukemia
Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT
The patients with relapsed B cell acute lymphoblastic leukemia (ALL) after hematopoietic stem cell transplant (HSCT) have a poor prognosis, especially for these relapsed in a short time after transplantation.
- Trial name
- NCT04516551
- Testing
- anti-CD19 allo-CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Xinqiao Hospital of Chongqing
Stem Cell Transplant Complications
Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Post HSCT
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapy for many malignant or nonmalignant hematological diseases.
- Trial name
- NCT04502628
- Testing
- Hyperbaric oxygen therapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shandong Provincial Hospital
Acute Lymphoblastic Leukemia, Myeloblastic Leukemia
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and calcineurin inhibitor in children and young adults with hematoloblastosis after myeloablative…
- Conditions
- Acute Lymphoblastic Leukemia, Myeloblastic Leukemia, Biphenotypic Acute Leukemia, Malignant Lymphoma
- Trial name
- NCT05515029
- Testing
- GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor
- Where
- Russia
- Volunteers
- 56 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Transplant-Related Disorder
daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT
This study aims to evaluate the efficacy of prophylactic ruxolitinib in adult patients at intermediate-to-high risk of severe acute GvHD, as predicted by the daGOAT model.
- Trial name
- NCT07588945
- Testing
- Ruxolitinib
- Volunteers
- 438 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
This randomized phase II trial studies how well giving tacrolimus and mycophenolate mofetil (MMF) with or without sirolimus works in preventing acute graft-versus-host disease (GVHD) in patients undergoing donor stem cell…
- Conditions
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome, Refractory Chronic Lymphocytic Leukemia, Refractory Plasma Cell Myeloma
- Trial name
- NCT00105001
- Testing
- Fludarabine Phosphate, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation
- Where
- 11 sites in United States, Denmark and 1 more
- Volunteers
- 210 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukaemia (Acute Lymphoblastic), Leukaemia (Acute Myeloid)
Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma
A first-in-class adoptive immunotherapy we called ThINKK, for Therapeutic Inducers of Natural Killer (NK) cell Killing, have been designed for use after hematopoietic stem cell transplantation (HSCT), where the proper stimulation…
- Conditions
- Leukaemia (Acute Lymphoblastic), Leukaemia (Acute Myeloid), Neuroblastoma, Neuroblastoma, Metastatic
- Trial name
- ThINKK-01 (NCT07518654)
- Testing
- Therapeutic Inducers of Natural Killer Killing (ThINKK)
- Where
- 2 sites in Canada
- Volunteers
- 12 people
- Sponsor
- Michel Duval
Infection
Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant
Patients enrolled on this study will have received a stem cell transplant. After a transplant, while the immune system grows back the patient is at risk for infection.
- Trial name
- CHARMS (NCT02108522)
- Testing
- Multivirus Specific T cells
- Where
- 2 sites in United States
- Volunteers
- 82 people
- Sponsor
- AlloVir
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Diabetes Mellitus
Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation
To investigate the impact of abnormal glucose tolerance in hematopoietic stem cell transplantation donors on patients' post-transplant survival outcomes.
- Conditions
- ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Diabetes Mellitus, Impaired Fasting Glucose
- Trial name
- NCT06704542
- Where
- 6 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Ruijin Hospital
CMV Infection, Hematopoietic Stem Cell Transplantation
Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies
Cytomegalovirus (CMV) remains a significant cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT).
- Trial name
- NCT05656599
- Testing
- Letermovir
- Where
- 2 sites in China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Obesity, Malignant Neoplasm
A Study to See if an iPhone Weight Management App Can Help Promote Weight Loss in Adolescents and Young Adults After a Stem Cell Transplant
This early phase I trial studies how well a behavioral weight loss intervention consisting of a smartphone application and coaching works for the promotion of weight loss in adolescents and young adults after a stem cell…
- Trial name
- NCT04453072
- Testing
- Interview, Media Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Jonsson Comprehensive Cancer Center
BK Virus Infection
Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B)
Patients enrolled on this study will have received a stem cell transplant. After a transplant, while the immune system grows back the patient is at risk for infection.
- Trial name
- NCT02313844
- Testing
- Viralym-B
- Where
- 2 sites in United States
- Sponsor
- AlloVir
Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis
Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
The purpose of this study is to determine a safe dose of BPX-501 gene modified T cells infused after a haplo-identical stem cell transplant to facilitate engraftment and the safety of Rimiducid (AP1903) on day 7 to prevent GVHD.
- Conditions
- Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis, Inherited Bone Marrow Failure Syndrome, Hemoglobinopathies
- Trial name
- NCT02231710
- Testing
- BPX-501 and Rimiducid
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Bellicum Pharmaceuticals
Critical Illness, Ventilated Patients
Critical Illness After Hematopoietic Cell Transplantation
This is a prospective, multicenter observational trial for patients who develop critical illness after hematopoietic cell transplantation.
- Conditions
- Critical Illness, Ventilated Patients, Hematopoetic Stem Cell Transplantation, Transplant Complication
- Trial name
- CARE-HCT (NCT07328724)
- Where
- 6 sites in China
- Volunteers
- 4,000 people
- Sponsor
- Peking University People's Hospital
Leukemia, Cancer
T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE
Patients are being asked to participate in this study because they have a cancer in their blood (such as leukemia or lymphoma) or myelodysplastic/myeloproliferative (pre-leukemia).
- Conditions
- Leukemia, Cancer, Lymphoma, Lymphoma, Hodgkin
- Trial name
- REGKINE (NCT00578461)
- Testing
- Ara C, Mesna, Cyclophosphamide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Baylor College of Medicine
EBV Infection, CMV Infection
Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
Subjects have a type of blood cell cancer, other blood disease or a genetic disease for which they received a stem cell transplant.
- Conditions
- EBV Infection, CMV Infection, Adenoviral Infection
- Trial name
- EAP CHALLAH (NCT01945619)
- Testing
- Trivirus-Specific CTLs
- Where
- 2 sites in United States
- Sponsor
- Baylor College of Medicine
Hematologic Neoplasms
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Background: People with blood cancers often receive blood or bone marrow transplants. But even with these treatments, the risk of relapse is high.
- Trial name
- NCT05327023
- Testing
- donor lymphocyte infusion, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Stem Cell Transplant Complications, Acute Graft Versus Host Disease
Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT： Cohort Study
This study aims to establish a cohort of 500 patients with hematological disease who undergoing allogeneic hematopoietic stem cell transplantation in the northwest region.
- Conditions
- Stem Cell Transplant Complications, Acute Graft Versus Host Disease, Acute Kidney Injury, Major Adverse Cardiac Events
- Trial name
- NCT06386445
- Testing
- Serum metabolomics sequencing
- Volunteers
- 500 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Hepatitis B
Effectiveness of the Hepatitis B Vaccine Post-Hematopoietic Stem Cell Transplant
Background: Stem cell transplants (SCTs) are important in treating many diseases. There are two main types of transplants. Autologous stem cells come from the person getting the cells.
- Trial name
- NCT03511794
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)